Literature DB >> 8786374

Specific pathological Tau protein variants characterize Pick's disease.

A Delacourte1, Y Robitaille, N Sergeant, L Buée, P R Hof, A Wattez, A Laroche-Cholette, J Mathieu, P Chagnon, D Gauvreau.   

Abstract

Pick's disease (PiD) is characterized by a pan-laminar frontotemporal cortical atrophy, widespread degeneration of the white matter, chromatolytic neurons, and Pick bodies (PB). Microtubule-associated Tau proteins are the main cytoskeletal components modified during the neurodegenerative changes. In the present study, pathological alterations of Tau proteins were investigated in the brains of five PiD cases at both neuropathological and biochemical levels, using the monoclonal antibody AD2 which recognizes a phosphorylation-dependent Tau epitope and strongly labeled PB. A large number of cortical and subcortical regions were studied on frozen materials. Tau proteins were analyzed on mono- and two-dimensional gel electrophoreses using a quantitative western blot approach. In all specimens, a 55 and 64 kDa Tau doublet was observed in limbic, frontal, and temporal cortices as well as in striatum and substantia nigra. In contract, Alzheimer's disease (AD) brains are characterized by the presence of the 55, 64, and 69 kDa Tau triplet whereas the 64 and 69 kDa doublet is more typical of the progressive supranuclear palsy and corticobasal degeneration. Thus, the 55 and 64 kDa doublet appears to be specific to PiD, less acidic than AD Tau proteins, and well correlated with the presence of PB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786374     DOI: 10.1097/00005072-199602000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  43 in total

1.  Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

Authors:  M E King; N Ghoshal; J S Wall; L I Binder; H Ksiezak-Reding
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Familial encephalopathy with neuroserpin inclusion bodies.

Authors:  R L Davis; P D Holohan; A E Shrimpton; A H Tatum; J Daucher; G H Collins; R Todd; C Bradshaw; P Kent; D Feiglin; A Rosenbaum; M S Yerby; C M Shaw; F Lacbawan; D A Lawrence
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Differential incorporation of tau isoforms in Alzheimer's disease.

Authors:  Marisol Espinoza; Rohan de Silva; Dennis W Dickson; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-05       Impact factor: 4.472

4.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

5.  Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation.

Authors:  Solomiia Boyko; Krystyna Surewicz; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

6.  Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments.

Authors:  M G Spillantini; M Goedert; R A Crowther; J R Murrell; M R Farlow; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

Review 8.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

9.  Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer's disease - Hyperphosphorylation and cleavage of 4- and 3-repeat tau.

Authors:  Hiroki Fujii; Tetsuya Takahashi; Tomoya Mukai; Shigeru Tanaka; Naohisa Hosomi; Hirofumi Maruyama; Norio Sakai; Masayasu Matsumoto
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

10.  Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene].

Authors:  Ana Velasco; Graham Fraser; Patrice Delobel; Bernardino Ghetti; Isabelle Lavenir; Michel Goedert
Journal:  FEBS Lett       Date:  2008-02-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.